|
CN105121715B
(zh)
|
2012-12-11 |
2018-10-26 |
艾伯特叶史瓦大学爱因斯坦医学院 |
高通量受体:配体鉴定方法
|
|
DK3172227T3
(da)
*
|
2014-07-21 |
2019-12-02 |
Delinia Inc |
Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
|
|
EP3482766B1
(en)
|
2014-08-11 |
2020-05-20 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
IL304950A
(en)
|
2015-04-10 |
2023-10-01 |
Amgen Inc |
Interleukin for the expansion of myotonic control T-2 cells
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
KR20240115933A
(ko)
*
|
2016-05-04 |
2024-07-26 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
CA3022331A1
(en)
|
2016-05-18 |
2017-11-23 |
Albert Einstein College Of Medicine, Inc. |
Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
CN109475628A
(zh)
|
2016-05-18 |
2019-03-15 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
CN110167957A
(zh)
*
|
2016-11-08 |
2019-08-23 |
德里尼亚公司 |
用于治疗自身免疫疾病的il-2变体
|
|
WO2018112069A1
(en)
|
2016-12-13 |
2018-06-21 |
Delinia, Inc. |
Multivalent regulatory t cell modulators
|
|
AU2017379900B2
(en)
|
2016-12-22 |
2024-12-05 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
WO2018129474A1
(en)
|
2017-01-09 |
2018-07-12 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
JP7165717B2
(ja)
|
2017-03-15 |
2022-11-04 |
パンディオン・オペレーションズ・インコーポレイテッド |
標的免疫寛容
|
|
EP3596118B1
(en)
|
2017-03-15 |
2024-08-21 |
Cue Biopharma, Inc. |
Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
|
|
EP3604538A4
(en)
|
2017-03-29 |
2020-12-30 |
University of Miyazaki |
LONG-ACTING ADRENOMEDULLINE DERIVATIVE
|
|
MX2019013517A
(es)
|
2017-05-24 |
2020-08-17 |
Pandion Operations Inc |
Inmunotolerancia dirigida.
|
|
WO2019104092A1
(en)
|
2017-11-21 |
2019-05-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
CA3083941A1
(en)
*
|
2017-12-06 |
2019-06-13 |
Pandion Therapeutics, Inc. |
Il-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
|
AU2018394189B2
(en)
|
2017-12-27 |
2023-12-21 |
Kyowa Kirin Co., Ltd. |
IL-2 variant
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
JP7534215B2
(ja)
|
2018-01-24 |
2024-08-14 |
ベイジン パーカンズ オンコロジー カンパニー リミテッド |
サイトカイン融合タンパク質
|
|
WO2019144309A1
(en)
*
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
|
EP3752178A1
(en)
|
2018-02-16 |
2020-12-23 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
US11359000B2
(en)
|
2018-03-28 |
2022-06-14 |
Bristol-Myers Squibb Company |
Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
|
|
EP3552738B1
(en)
*
|
2018-04-12 |
2024-07-31 |
Sandvik Machining Solutions AB |
A method of producing an additive manufactured object
|
|
WO2019246404A1
(en)
|
2018-06-22 |
2019-12-26 |
Cugene Inc. |
Interleukin-2 variants and methods of uses thereof
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
US12459980B2
(en)
|
2018-07-25 |
2025-11-04 |
AskGene Pharma, Inc. |
IL-21 prodrugs and methods of use thereof
|
|
CA3108865A1
(en)
|
2018-08-06 |
2020-02-13 |
Medikine, Inc. |
Il-2 receptor binding compounds
|
|
US12403181B2
(en)
|
2018-08-13 |
2025-09-02 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
JP7543269B2
(ja)
|
2018-12-21 |
2024-09-02 |
ジエンス ヘンルイ メデイシンカンパニー リミテッド |
ヒトインターロイキン２の変異体またはその誘導体
|
|
WO2020160242A1
(en)
|
2019-02-01 |
2020-08-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-il2 receptor gamma antigen-binding proteins
|
|
CA3129317A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
|
KR20210128443A
(ko)
|
2019-02-15 |
2021-10-26 |
인테그럴 몰큘러 인코포레이티드 |
클라우딘 6 항체 및 이의 용도
|
|
EP3972992A4
(en)
|
2019-05-20 |
2023-07-19 |
Pandion Operations, Inc. |
MADCAM TARGETED IMMUNOTLERANCE
|
|
WO2020252264A1
(en)
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
PH12022550165A1
(en)
|
2019-07-26 |
2023-05-08 |
Visterra Inc |
Interleukin-2 agents and uses thereof
|
|
CA3148505A1
(en)
*
|
2019-08-12 |
2021-02-18 |
AskGene Pharma, Inc. |
Novel il-2 fusion molecules
|
|
JP7427286B2
(ja)
|
2019-11-05 |
2024-02-05 |
メディカイン、インコーポレイテッド |
ＩＬ－２ＲβγＣ結合化合物
|
|
AU2020378282B2
(en)
|
2019-11-05 |
2023-05-18 |
Medikine, Inc. |
Dual IL-2R and IL-7R binding compounds
|
|
KR20220139293A
(ko)
|
2019-12-12 |
2022-10-14 |
일투 파마 |
인터류킨 2 키메라 구축물
|
|
US20210188934A1
(en)
*
|
2019-12-20 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Novel il2 agonists and methods of use thereof
|
|
US11491205B2
(en)
|
2020-01-14 |
2022-11-08 |
Synthekine, Inc. |
Biased IL2 muteins methods and compositions
|
|
JP2023512687A
(ja)
|
2020-02-03 |
2023-03-28 |
メディカイン、インコーポレイテッド |
ＩＬ－７Ｒα結合化合物
|
|
KR20220139918A
(ko)
|
2020-02-03 |
2022-10-17 |
메디카인 인코포레이티드 |
IL-7Rαγc 결합 화합물
|
|
WO2021168079A1
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
|
US11028132B1
(en)
|
2020-04-07 |
2021-06-08 |
Yitzhak Rosen |
Half-life optimized linker composition
|
|
EP4149534A4
(en)
|
2020-05-12 |
2024-09-04 |
Cue Biopharma, Inc. |
MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
|
|
WO2021231773A1
(en)
|
2020-05-13 |
2021-11-18 |
Good Therapeutics, Inc. |
Compositions of protein complexes and methods of use thereof
|
|
US20230340054A1
(en)
*
|
2020-09-01 |
2023-10-26 |
Takeda Pharmaceutical Company Limited |
Interleukin-2 muteins and uses thereof
|
|
WO2022056014A1
(en)
|
2020-09-09 |
2022-03-17 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
|
|
IL302276A
(en)
|
2020-10-23 |
2023-06-01 |
Asher Biotherapeutics Inc |
Fusions with cd8 antigen binding molecules for modulating immune cell function
|
|
WO2022094275A1
(en)
|
2020-10-29 |
2022-05-05 |
Bristol-Myers Squibb Company |
Fusion proteins for the treatment of disease
|
|
TW202227123A
(zh)
|
2020-11-13 |
2022-07-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種包含人白細胞介素２變體或其衍生物的醫藥組成物及其用途
|
|
EP4255466A1
(en)
|
2020-12-04 |
2023-10-11 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
IL304365B2
(en)
*
|
2021-03-31 |
2025-04-01 |
Hanmi Pharmaceutical Co Ltd |
A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
|
|
MX2023011930A
(es)
|
2021-04-09 |
2024-03-11 |
Selecta Biosciences Inc |
Nanoportadores sintéticos que comprenden un inmunosupresor en combinación con antagonistas del receptor de il-2 de alta afinidad para mejorar la tolerancia inmune.
|
|
MX2024004291A
(es)
|
2021-10-06 |
2024-06-28 |
Iltoo Pharma |
Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados.
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20230263906A1
(en)
|
2022-01-10 |
2023-08-24 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
|
|
WO2023172628A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
|
|
WO2023183568A1
(en)
|
2022-03-25 |
2023-09-28 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
US11999771B2
(en)
|
2022-04-07 |
2024-06-04 |
Medikine, Inc. |
IL-7Rαγc ligand immunoglobulin fusion proteins
|
|
US20230381277A1
(en)
|
2022-04-08 |
2023-11-30 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
|
|
CN115322260A
(zh)
*
|
2022-06-13 |
2022-11-11 |
杭州高田生物医药有限公司 |
能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用
|
|
CA3265946A1
(en)
|
2022-09-12 |
2024-03-21 |
Univ Sorbonne |
INTERLEUKIN-2 FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS
|
|
IL319951A
(en)
|
2022-11-30 |
2025-05-01 |
Integral Molecular Inc |
Antibodies targeting claudin 6, including its bispecific formats
|
|
AU2024207151A1
(en)
|
2023-01-09 |
2025-06-19 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
|
WO2024229370A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Compositions and methods for treating gvhd
|
|
WO2024229432A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
|
|
WO2024229350A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
|
|
WO2024229380A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|